Skip to main content

Advertisement

Table 1 Patient attributes

From: Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer

Item Non intervention Intervention P
n (%) n (%)
Age (year)
 Mean ± Standard deviation 53.3 ± 11.1 56.3 ± 9.0 0.313
Gender
 Female 19 (100) 20 (100) 1.000
 Male 0 (0) 0 (0)
PS
 0 19 (100) 20 (100) 1.000
 1 0 (0) 0 (0)
 2 0 (0) 0 (0)
Stage
 I 3 (16.7) 8 (38.1) 0.238
 II 8 (44.4) 11 (52.4)
 III 5 (22.2) 2 (9.5)
 IV 3 (16.7) 0 (0)
HER2
 0 1 (5.6) 1 (4.8) 0.213
 + 1 9 (44.4) 13 (61.9)
 + 2 6 (33.3) 2 (9.5)
 FISH- 4 2
 FISH+ 2  
 + 3 3 (16.7) 5 (23.8)
ER    
 + 15 (77.8) 15 (71.4) 0.223
 ± 2 (11.1) 4 (19.0)
 – 2 (11.1) 2 (9.5)
PgR    
 + 10 (55.6) 11 (52.4) 0.223
 ± 4 (16.7) 5 (23.8)
 – 5 (27.8) 5 (23.8)
Purpose of chemotherapy    
 Neoadjuvant 11 (61.1) 8 (40.0) 0.343
 Adjuvant 8 (38.9) 12 (60.0)
Regimen    
 Anthracyclines    0.110
  EC (every 3w) 11 (61.1) 11 (55.0)
  FEC (every 3w) 0 (0) 3 (15.0)
 Taxanes   
  TC (every 3w) 3 (16.7) 6 (30.0)
  nabPTX (every 3w) 1 (5.6) 0 (0)
  PTX + BV (every 4w) 1 (5.6) 0 (0)
 Others   
  CMF (every 3w) 3 (16.7) 0 (0)
Marital status    
 Married 13 (68.4) 16 (80.0) 0.480
 Unmarried 6 (31.6) 4 (20.0)
Cohabitants    
 Yes 19 (100) 19 (95.0) 1.000
 No 0 (0) 1 (5.0)
Current occupation    
 Employer 12 (63.2) 9 (45.0) 0.341
 Non-employee 7 (36.8) 11 (55.0)
  1. Fisher’s exact test, PS performance status, HER2 human epidermal growth factor receptor type 2, ER estrogen receptor, PgR progesterone receptor, EC epirubicin/cyclophosphamide, FEC fluorouracil/epirubicin/cyclophosphamide, TC docetaxel/cyclophosphamide, nab-PTX nanoparticle albumin-bound paclitaxel, PTX paclitaxel, BV Bevacizumab, CMF cyclophosphamide/methotrexate/fluorouracil